⌕
Royalty Pharma · RPRX · Nasdaq
Tenet 35 · Weak
Compare
$69.31+0.49%At closeTenet 35 · Weak
$69.31+0.34 (+0.49%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD
$68.19
After hours: Nov 16, 2026, 4:07 PM ET

Royalty Pharma (RPRX) Stock

Royalty Pharma (RPRX) closed at $69.31 on Nov 13, 2026; its Tenet Score is 35 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

13 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$69.31
Nov 13, 2026
Market cap
$39.8B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
57.4×
price ÷ earnings
Dividend yield
1.36%
past year's regular dividends ÷ price
52-week range
37.31 – 70.37
low → high · as of close, Nov 13, 2026
Tenet Score
35/100
Weak · 313 Healthcare peers

Industry: Financial Services

Royalty Pharma plc scores 35/100. Weak. Strongest on quality, growth is the soft spot, trading at 57× earnings versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
35/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
32
Quality
68
Health
26
Growth
14

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityCHealthFGrowthFMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
5.8×
price to book value
P/S
15.2×
price to fiscal 2025 sales
ROE
12%
return on equity
Operating margin
65.6%
fiscal 2025, before interest and tax
Net margin
44.8%
of revenue kept
Current ratio
1.29
current assets to liabilities
Net debt / EBITDA
—
Not reported in the company's filings for this period.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharm…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 205 US ETFs · top wrappers by weightSee all ETFs holding RPRX →

Similar-sized companies in Financial Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

Compare Royalty Pharma with

What sector and industry is Royalty Pharma in?

Royalty Pharma is in the Healthcare sector and the Financial Services industry.

What is Royalty Pharma's Tenet Score?

Royalty Pharma's Tenet Score is 35 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.